Akebia Therapeutics, Inc.
- AKBA
- NASDAQ
- Biotechnology
- Kidney Disease Therapeutics
- Oral Anemia Treatment
$0.67
Today −3.67%Quote Oct 16, 2026, 08:00 PM UTC
−25.18%over the last month
Max drawdown −31.6%From 1-month high −31.6%3 months −47.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$185.7M
Quote Oct 16
Next earnings
Nov 9
Expected, not confirmed
Analyst target
$1.00
+49.3% from here
Floor
$0.64
4.1% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about AKBAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $49.1M
- License, Collaboration And Other Revenue$2.4M4.8%
- Supply Agreement$500,0001.0%
- License Collaboration And Other Revenue, Royalties$100,0000.2%
- Other / not reported$46.2M94.0%
Industry
Biotechnology
Employees
194